Leflunomide

證據等級: L5

預測適應症: 2 個

Leflunomide: From Rheumatoid Arthritis to Brachydactyly-Syndactyly Syndrome

One-Sentence Summary

Leflunomide is a disease-modifying antirheumatic drug (DMARD) established internationally for the treatment of rheumatoid arthritis and psoriatic arthritis. The TxGNN model predicts it may be effective for Brachydactyly-Syndactyly Syndrome, an ultra-rare congenital limb malformation disorder. However, no clinical trials or published literature support this direction, and the mechanistic rationale identified by the knowledge graph contains a critical directional flaw that renders this a likely false positive.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis / psoriatic arthritis (established internationally; no NL authorization recorded in this dataset)
Predicted New Indication	Brachydactyly-Syndactyly Syndrome
TxGNN Prediction Score	99.93%
Evidence Level	L5
NL Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on established pharmacology, Leflunomide is an inhibitor of dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in de novo pyrimidine biosynthesis. By depleting intracellular pyrimidine pools, it suppresses proliferation of activated T and B lymphocytes, producing its anti-inflammatory effect in rheumatoid arthritis.

The knowledge graph (KG) likely traced the following path to generate this prediction: loss-of-function (LOF) mutations in the DHODH gene are known to cause Miller syndrome, a rare disorder characterised by acrofacial dysostosis including limb abnormalities. The KG may have established an indirect association between the DHODH gene node and brachydactyly/syndactyly phenotype nodes, giving rise to a high-confidence score.

However, this connection represents a mechanistic direction inversion false positive. The congenital phenotype arises from insufficient DHODH activity (LOF), while Leflunomide further inhibits DHODH — meaning the drug acts in the same direction as the underlying pathological mechanism rather than opposing it. Applying a DHODH inhibitor to treat a disorder caused by DHODH deficiency is pharmacologically counterproductive. This prediction does not carry therapeutic plausibility and should be treated as a model artefact.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Netherlands Market Information

No CBG-MEB national authorization (RVG number) for Leflunomide is recorded in this dataset.

Note: Leflunomide (brand name Arava) is authorized in the European Union via centralized EMA procedure. EU-wide authorizations (EU/x/xx/xxx format) may not be captured in national RVG datasets. Clinicians and pharmacists should verify current authorization and market availability directly via the CBG-MEB product database or the EMA medicines portal before drawing conclusions about NL accessibility.

Safety Considerations

Please refer to the SmPC (Summary of Product Characteristics) for safety information. Safety data — including key warnings, contraindications, and drug interactions — was not available in this evidence pack.

Given that Leflunomide holds a well-established EMA authorization for rheumatoid arthritis, a current SmPC is available via the EMA website and should be consulted for any clinical use.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction for brachydactyly-syndactyly syndrome is a mechanistic direction inversion false positive: the disorder is caused by DHODH loss-of-function, while Leflunomide inhibits DHODH — the drug would exacerbate rather than correct the underlying pathophysiology. Combined with an evidence level of L5 (zero clinical trials, zero publications), there is no basis to advance this indication.

To proceed constructively, the following is needed:

Flag this prediction as a false positive in the TxGNN pipeline; consider implementing a mechanistic directionality filter for enzyme LOF/inhibitor pairs
Do not initiate any clinical or translational study for this indication without independent mechanistic re-evaluation
Verify NL market status via CBG-MEB / EMA databases — Leflunomide likely holds an EU centralized authorization not captured in this national dataset
Retrieve SmPC safety data (warnings, contraindications, hepatotoxicity monitoring requirements) before any clinical consideration of the drug in the Netherlands
If exploring Leflunomide for novel indications, prioritize inflammatory or immune-mediated disease phenotypes where DHODH inhibition is mechanistically coherent (e.g., lupus nephritis, inflammatory bowel disease — indications with existing investigational literature)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.